It is shown that if the numerical values of the coefficients and exponents of the polyexponentiaI
INTRODUCTION
In a linear pharmacokinetic system, plasma concentrations following bolus intravenous injection, i.v. C~; , will be described by a polyexponential Supported in part by Public Health Service Grant 5P11 GM 15559.equation as in equation 1 . Expanded forms of equation 1, corresponding to one, two, and three exponential terms are shown as equations 2-4, respectively.
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In equations 1-4, Ci (C1, Ce, C3) are the coefficients, Ai (AI, Az, A3) are the exponents, and t is time.
The numerical values of the C~'s and Ai's of equation 1 obtained from a given set of data depend on (a) the specific linear pharmacokinetic model (including exactly how many exit rate constants there are and where they exit from the one or more compartments), (b) the numerical values of the rate constants (kq's and k,o 's), (c) the dose, D, of the drug, and (d) the volume of the plasma (reference) compartment, Vp.
In another article (1) , it is shown that one and sometimes two terms of the polyexponential equation describing the plasma concentration after either intravenous or oral administration can readily vanish a few minutes after administration. This fact, coupled with the more complicated, nonclassical linear models discussed in that article, indicates that most of the time we cannot even determine which class of model we are dealing with. Also, there is no a priori reason to assume that all subjects or patients in a panel should have the same model for a drug.
When only whole blood (plasma or serum) concentration-time data and/or urinary excretion data are available, there is really no rigorous method to determine whether elimination occurs only from the central (reference) compartment or from one or more of the peripheral compartments or both. Thus when evaluating such data the pharmacokineticist is presented with a dilemma. We have really not confronted this problem adequately to date. It has become customary in pharmacokinetics to assume one specific model for a given drug administered to a panel of subjects or patients, then to "force this specific model" on all sets of data, and to derive various kinetic parameters. There are three two-compartment open models, all of which give an equation of the form of equation 3 after bolus intravenous injection, There are 21 three-compartment open models, all of which give an equation of the form of equation 4 after bolus intravenous injection. We do not have the methods available to determine from the C~'s and Ai's of equation 1 which class of models or which specific model applies to a given set of data in either of these situations. In fact, relative to the disposition model, unless special sampling procedures are used to detect peripheral metabolism or excretion, we have no recourse but to assume that all elimination processes occur only from the central compartment.
Three proposals are being made in this article. These are as follows:
1. Assume (unless there is strong evidence to the contrary) that the general modet which applies is an n-compartment mammiUary model with elimination only from the central (reference) compartment as shown in Scheme I. 
THEORETICAL
Symbolism
A5 is the amount of drug in the "body" (i.e., all compartments) at time t.
(As)~ is the amount of drug in the "body" (all compartments) at time t in the terminal log-linear phase (i.e., only Cle -xlt is still contributing). A~ s is the amount of drug in the "body" (all compartments) at time t at steady state. A i s is the average amount of drug in the "body" (all compartments) at steady state. Ae is the amount of drug which has been eliminated (metabolized and/or excreted) from the "body" in time t. Ap is the amount of drug in the plasma (reference) compartment at time t. Ao = A5-Ap is the amount of drug in compartments other than the plasma or reference compartment at time t. AUC is the area under the plasma concentration-time curve (subscripts give limits). Bi (i = 1, 2 .... , n) is the coefficient of the ith exponential term of the polyexponential equation describing the plasma concentration following oral administration (i.e., analogous to equation 1 except that Bi replaces Ci). C~ (i = 1, 2,..., n) is the coefficient of the ith exponential term of the polyexponential equation describing the plasma concentration following bolus intravenous administration. Clp is the plasma clearance (dimension of volume/time). Cp is the plasma concentration (i.e., concentration in the reference compartment with volume Vp) at time t. C iv refers to bolus intravenous administration and CPl ~ refers to oral administration. ~s is the plasma concentration at time t at steady state. Eij is the exit rate constant for the ith compartment and equals the sum of all first-order rate constants whose arrowheads point away from the ith compartment. F is the bioavailability factor concerned with incomplete absorption of the dose. F* is the bioavailability factor concerned with the so-called first-pass effect. This is defined by equation 28 when F = 1. For a given model, F* is a combination of rate constants and F* _< 1. f is the fraction of the drug which is free in the whole body. kij is a first-order "microscopic rate constant" for transfer of drug from the ith to the jth compartment.
kio is a first-order "microscopic rate constant" for transfer of drug from the ith compartment to outside "the body" or elimination rate constant of the ith compartment. k0 is the constant intravenous infusion rate (dimensions of mass/time). Ai is the exponent multiplying t in the exponential terms. Usually each Ai will be an eigenvalue which is the absolute value of one of the roots when the determinant is set equal to zero; in this case, the A~ is a function of all or many of the k~j's and kio's of the model. In some cases, the A~ is equal to one of the kq's. Note that A1 is the smallest Ai (classically symbolized by fl), A 2 is the second smallest Ai, etc.; i.e., the order of Ai's with respect to magnitude is the same as that obtained by stripping the data. Note that A~ refers to bolus intravenous administration or constant infusion and A~ p~ refers to oral administration. Oi (i = 1 or 2) are infusion rates (see equations 31 and 32 and text nearby). S; (i = 1 ..... 5) are particular sums defined by equations 5-9. y =E. o" is the fraction of the drug which is free (not protein bound) in plasma.
ll/2 is the apparent elimination half-life of the drug.
T is the duration of a constant-rate intravenous infusion (dimension of time). r is the uniform dosage interval (dimension of time). to is a lag time sometimes introduced into a polyexponential equation for C p'~ for oral administration (dimensions of time).
ts~ ~ is the time of the maximum plasma concentration after oral dosing at steady state. V/3 or Vdare a is defined by equations 6 and 13.
Vuss is the volume of distribution at steady state (based on the model of Scheme I).
Vas~C'v s is the amount of drug in the body at time t at steady state. Va~C~p ~ is the average amount of drug in the body at steady state. V, is the volume of the plasma (reference) compartment.
X~ is the coefficient of the ith exponential term of the polyexponential equation giving the plasma concentration during constant-rate intravenous infusion. Y~ is the coefficient of the ith exponential term of the polyexponential equation giving the plasma concentration after a constant rate infusion has ceased.
Equations
Equations for Bolus Intravenous Injection 3
The plasma concentration is described by equation 1. Let
(8)
Then the plasma clearance, Clp, is defined by equation 10.
The volume of the plasma compartment, Vp, is given by equation 11.
(11)
The volume of distribution at steady state, Vas~, is given by equation 12.
Wd .... or Vt~ is given by equation 13.
3See Appendix for some derivations.
The extrapolated volume of distribution, Vaext, is given by equation 14.
vd ex, = D~ C1 (14)
The elimination half-life, tl/2, is given by equation 15.
The amount which has been metabolized and/or excreted to time t, Ae, is given by equation 16.
It should be emphasized that equation 16 is mathematically correct only when elimination occurs solely from the central compartment. The amount of drug in the body at time t, Ab, is given by equation 17 (1) .
The amount of drug in the plasma compartment at time t, A e, is given by equation 18.
The amount of drug in other compartments than the plasma compartment at time t, Ao, is given by equation 19.
Equations 19, in effect, lumps n peripheral compartments into one peripheral compartment. The time-dependent volume of distribution, (Va)t, is given by equation 20, originally derived by Niazi (2) .
It should be noted that the order of magnitudes of the volumes is always
Vdoxt> Vdaro.> Vdss> Vp
It should also be noted that (Ab)t~ = Vaare. " Cp, since (Va)t = Vd.r~. in the log-linear phase when all exponential terms, except e -~lt, essentially equal zero.
Relationship Between Bolus Intravenous and Infusion Equations
The relationships between the bolus intravenous and intravenous infusion equations are shown in Table I for expansions up to and including three exponential terms. During a constant-rate intravenous infusion (t ~ T) the plasma concentration is described by equation 21, and after the infusion has ceased (t -~ T) the plasma concentration is described by equation 22.
= E X/(1 -e -*,t) =EA@T(1 -e -a't) G fe +~'T l/ G=E Y~e =LG By matching coefficients, we see that Equations 26 and 27 include a lag time, to, which may be a positive value or zero. The program CSTRIP(3) automatically determines whether a lag time is needed to describe a given set of oral data. If to = 0, then Bi = B;.
It should be noted that B~ can replace C~ and A p~ can replace Ai in equations 5 and 6. The result would give the sums S p~ and S p'~ respectively. If the latter values are then used in equations 10 and 13, with substitution of Dp (1-e *~')
_.,, 
Drugs Bound to Plasma Protein and Tissues
If or is the fraction of the drug which is free (not protein bound) in plasma, f is the fraction of the total drug in the body which is free, (A :)F is the intrinsic apparent elimination rate constant referenced to free drug, A 1 is the apparent elimination rate constant obtained from Cp, t data, and the onecompartment open model with linear plasma protein binding and linear tissue binding applies, then
For this particular one-compartment open model, Va .... = Vaext and both depend on bothf and or. This will be explained in a future publication by the author.
Safe and Rapid Attainment of Steady-State Plasma Concentrations
Once A1 and Clp are known for a linear system and a particular subject (or average parameter values are used), then steady-state plasma levels may be safely and rapidly attained by the method of Wagner (4). The steps are as follows:
1. Choose the desired steady-state plasma concentration, C~ s. 2. Choose the time T for the duration of the initial constant-rate intravenous infusion at the rate QI (mass/time). [
Similar equations to 34-38 may be used for bolus intravenous injections given at intervals of ~" hr, but Bi is replaced by Ci and A p.o. is replaced by Ai (i.e., one uses equation 1 in place of equation 26). When the intravenous route is used, then the average steady-state plasma concentration, C~ s, is given by equation 39 (6) .
If one substitutes the maintenance dose, D,,, the clearance, Clp, and the dosage interval, r, into the right-hand side of equation 39 for oral administration, the quantity estimated is CpS/FF * (since drug reaching the circulation is FF*Dm and not Din). However, if one had estimated an apparent plasma clearance, Clp/FF*, from oral data and used it in place of Clp in equation 39, then C~would be estimated. There is much confusion in the literature about such calculations.
There is also some confusion in the literature as to what "clearances" mean. Various "clearances" were calculated for diphenhydramine from plasma concentrations measured both during and after a constant-rate intravenous infusion and after oral administration of similar (but known) doses of the drug given as an aqueous solution and in capsule form (7) . Results obtained may be summarized as shown in Table II . It is obvious that F and F* are confounded. We can obtain an estimate of F* only if we assume F~ = 1 for the solution given orally.
EXPERIMENTAL Example of Obtaining Coefficients of Bolus Intravenous Equations from Postinfusion Data
For the two-compartment open model with elimination only from the central compartment, let k12=3, k21 = 2, kel=0.1, Di.v.= 500,000, lip = 5000, ko = 250,000, and T= 2. For these constants, we find A1 = 0.03952 and A2 = 5.0605 (see Appendix). For bolus intravenous injection, Di.v.
cp-vp(a2-A1) [(k21--A1) e -x't-(k21-A2) e -~2t]
(40) 
The difference of 1 in 12,500 is due only to round-off error in the C~'s and hl's.
Example 2
Example 2 is of a three-compartment open model with elimination only from the central compartment shown in Scheme II. The dose is put into compartment 1 at time zero. The Laplace transform of the amount of drug in compartment 1 at t, al, is given by equation 55.
Letting C~ v" =Al/Wp, and taking the antitransform of equation 55, gives
For example, let k12 = 3, k21 = 2, k13 = 1, k31 = 0.5, klo = 0.1, Di.v. = 500,000, and Vp = 5000. Then The value of Vds~ given by equation 12 will exactly coincide with the value given by equation 65 only when the particular three-compartment open model shown in Scheme II is involved. However, since we usually cannot determine from which compartments elimination occurs, this is part of the pharmacokineticist's dilemma. Hence unless there are good reasons for the contrary, the author suggests that Vd~s always be calculated by means of equation 12.
DISCUSSION
As discussed earlier (1, 5) , there are many alternative models, all of which yield a two-or three-term exponential equation as illustrated by equations 3 and 4. It is getting to be common practice to measure some pharmacological response as a function of time and occasionally to conclude that the response is related to the amount of drug in compartment 1, compartment 2, or compartment 3. An alternative recommendation is to fit the data to the required number of exponential terms, then to determine if the response is approximately related to Ab (from equation 17) or Ao (from equations 17-19). This will tell one whether the site of action is in "the plasma compartment" or "some other part of the theoretical body" according to pharmacokinetic theory. However, the use of equations 17-19 will in effect lump all peripheral compartments into one compartment. Whether this is a better alternative requires further study. It is important to know which compartment may relate to specific responses for specific drugs so that appropriate predictions and explanations may be made. To carry out such a determination accurately requires that plasma concentrations and responses be measured more than once shortly after intravenous administration as well as at later times. This is so since Ab is a maximum at time of injection and falls off whenever Ao is zero at time zero, rises to a maximum at some later time, and then falls off. Hence the distinction is made readily with data collected shortly after intravenous administration.
Another point concerns degrees of freedom and what should be reported. If a bolus intravenous dose is administered and the plasma concentrations are fitted to a three-term exponential equation (equation 4), then one can report only six items as indicated by equation 4, namely C1, C2, C3, A1, A2, and A3.
Fitting the data to equation 4 is a model-independent process. However, one must realize that A i values must be widely separated (i.e., greater than two-to fivefold) for one to accept the validity of any computer fit. A six-parameter equation probably requires 18 or more data points properly spaced throughout the Cp,t curve. Assuming relatively accurate measurement, such data may yield a reasonable estimate of the parameters if the resultant Ai values are sufficiently separated as noted above. Otherwise, the computer-derived exponentials must be considered as only our tentative, probably inaccurate estimate of the appropriate equation.
If the data set fits the above restrictions, one can apply the equations listed in this article. Most of the equations 5-20 are model independent. However, equations 16 and 19 are model dependent, as noted earlier when they were originally discussed. Hence for consistency from one author to another it is here proposed that all authors use the general model shown in Scheme I and the general equations for this general model given in this article.
Parameters
tl/2
The plasma half-life, hi2, may be defined as the time required for the plasma concentration to fall to one-half its value after absorption has ceased and pseudo-steady-state distribution has been attained. The latter, for practical purposes, means that the amount of drug in each peripheral compartment is falling off essentially at the same first-order rate as the amount of drug in the central (reference) compartment. Hence tl/2 is the apparent elimination half-life. It is defined by equation 15, and, in the symbolism section, A1 is defined as the smallest of the Ai values. If the "rules are obeyed" and terminal plasma concentrations are well fitted by the polyexponential equation, then this definition is satisfactory. It will be h 1 which has the most influence of all the Ai values in determining C~ i~ (see equation 37) and Cp S (see equations 39 and 10). The problem of not having a sensitive enough assay to "see" the correct value of ,~ 1, and the errors which ensue, has been discussed by Wagner (7) . If Cp, t data have been correctly computer-fitted to the general polynomial equation, this parameter, as with all other coefficients and exponentials, is really model independent, and does not rely on the general model shown in Scheme I.
Half-lives estimated from the other eigenvalues or kij's, such as 0.693/A2 and 0.693/A3, have frequently been termed "distribution halflives." But there are problems with such interpretations. If eigenvalues are involved, then they are a function of all the rate constants in the system and not just the microscopic distribution rate constants. If the coefficients and exponents of the polyexponential equation which is the "best fit" of each set of data are reported by an author, there appears to be no need to report the corresponding half-lives, since they may be readily calculated from the hi values. The terminal tl/2 (calculated from A 1) is the lone exception, and the reason for this is that scientists are used to thinking in terms of an elimination half-life rather than in terms of an apparent first-order elimination rate constant.
Vdext
By the nature of its calculation (equation 14), Vaext is also model independent, and does not actually rely on the general model shown in Scheme I. However, one of the commonest errors made in the literature is to assume that after a bolus intravenous injection Clp = Vaext" A1. This is true only when Vaext = Vaarea, as is the case with some drugs such as warfarin. The requirements for such a situation have been discussed by Albert et al. (8 If each set of data from a panel of subjects or patients is fitted with the appropriate number of exponential terms for each subject, then Vp is also truly model independent, and does not rely on the general model shown in Scheme I. However, if one fits a given set of data to a biexponential equation when the data really require a triexponential equation, then the value of Vp estimated from the two equations will be different.
•dss
The Vass value calculated with equation 12 applies only to the general model shown in Scheme I. However, because of the dilemma of not knowing from which compartments there are exit rate constants to "outside the body," use of equation 12 will at least make all authors homogeneous in their approach. 
Wdarea
Ae, Ab, and Ao
Expressions Ae, Ab, and Ao calculated with equations 16, 17, and 19 are dependent on the general model shown in Scheme I.
Conclusion
Most pharmacokinetic articles on specific drugs report some or all of the parameters discussed above. The advantage of the equations in this article is that all of them may be calculated directly from the coefficients and exponents of the polyexponential equation without deriving any microscopic rate constants. 
Abd r=DZJo ai(l_e_a,~)e-A'td rZG/ai
Omitting the sum sign temporarily, we find that Hence we may write the infusion equations as shown in Table I and  equation 21. Post-intravenous-infusion equation 93 applies to Scheme IV.
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Utilizing equations 84, 86, and 95, we obtain equations 97-99. 
Hence we may write the infusion equations as shown in Table I and  equation 22. 
